title: Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma.
abstract: BACKGROUND
  MUC5AC is a secreted mucin aberrantly expressed by colorectal polyps and carcinoma. It has been hypothesized that aberrant expression of MUC5AC in colorectal carcinoma tissues increased the overall survival of patients with colorectal carcinoma. The present study investigates the incidence of naturally occurring MUC5AC antibodies in the sera of normal individuals, patients with colonic polyps and patients with advanced colorectal carcinoma. A second aim was to determine the relationship of MUC5AC antibody with the prognosis of colorectal carcinoma.
  
  
  METHODS
  Free circulating MUC5AC antibodies were measured using an enzyme-linked immunosorbent assay with a synthetic peptide corresponding to an 8 aa. segment of MUC5AC tandem repeat region. Immunohistochemical analysis was completed to demonstrate MUC5AC expression in the polyp specimens.
  
  
  RESULTS
  MUC5AC antibodies were detected in 6 of 22 (27.3%) healthy subjects, 9 of 20 (45%) polyp patients, 18 of 30 (60%) patients with colorectal cancer. The presence of circulating free MUC5AC antibody levels was significantly correlated with expression of MUC5AC in polyp sections. Serum MUC5AC antibody positivity was higher in patients with colon located tumors, advanced stage and poorly differentiated tumors were found negatively affecting patient survival in our study. MUC5AC antibody positivity was higher in patients with poor prognostic parameters. Disease free survival and overall survival were shorter in this group of patients. In the multivariate analysis MUC5AC antibody positivity didn't find an independent prognostic factor on prognosis.
  
  
  CONCLUSIONS
  Decreased survival in colorectal carcinoma patients with MUC5AC antibody positivity may be due to a decrease in the MUC5AC expression in tumor tissues of surviving carcinoma patients.
authors.affiliation: Department of Immunology, University of Pittsburg School of Medicine, Pittsburgh, PA, USA. belmak@lycos.com
authors.forename: Belma
authors.initials: B
authors.lastname: Kocer
authors.forename: John
authors.initials: J
authors.lastname: McKolanis
authors.forename: Atilla
authors.initials: A
authors.lastname: Soran
mesh_terms: D000328:Adult; D000368:Aged; D000917:Antibody Formation; D001323:Autoantibodies / Q000097:blood; D002277:Carcinoma / Q000276:immunology*; D016022:Case-Control Studies; D003111:Colonic Polyps / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007417:Intestinal Polyps / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D055271:Mucin 5AC; D009077:Mucins / Q000276:immunology*; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D012007:Rectum / Q000276:immunology; D016019:Survival Analysis
chemical_list: D001323:Autoantibodies; C524678:MUC5AC protein, human; D055271:Mucin 5AC; D009077:Mucins